SAR 260301
Alternative Names: SAR260301Latest Information Update: 18 Oct 2017
At a glance
- Originator Sanofi
- Class Antineoplastics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Malignant melanoma; Solid tumours
Most Recent Events
- 04 Oct 2017 Sanofi completes a phase I trial for Lymphoma, Solid tumours and Malignant melanoma (Late-stage disease) in USA and Canada (PO) (NCT01673737)
- 05 Feb 2015 Discontinued - Phase-I for Malignant melanoma (Late-stage disease) in Canada (PO)
- 05 Feb 2015 Discontinued - Phase-I for Lymphoma (Late-stage disease) in Canada (PO)